[go: up one dir, main page]

UY30284A1 - Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 - Google Patents

Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3

Info

Publication number
UY30284A1
UY30284A1 UY30284A UY30284A UY30284A1 UY 30284 A1 UY30284 A1 UY 30284A1 UY 30284 A UY30284 A UY 30284A UY 30284 A UY30284 A UY 30284A UY 30284 A1 UY30284 A1 UY 30284A1
Authority
UY
Uruguay
Prior art keywords
dopamine
appropriate
treat disorders
receptor modulation
aryloxyethylamine
Prior art date
Application number
UY30284A
Other languages
English (en)
Inventor
Liliane Unger
Karla Drescher
Udo Lange
Sean Colm Turner
Andreas Haupt
Wilfried Martin Braje
Roland Grandel
Original Assignee
Abbott Gmbh & Amp
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Amp, Co Kg filed Critical Abbott Gmbh & Amp
Publication of UY30284A1 publication Critical patent/UY30284A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a compuestos de ariloxietilamina de la formula y las sales de adicion ácida toleradas fisiologicamente de los mismos. Las variables tienen los significados dados en las reivindicaciones y en la memoria descriptiva. El uso de un compuesto de la formula I o una sal aceptable para uso farmacéutico del mismo para preparar una sal aceptable para uso farmacéutico del mismo para preparar una composicion farmacéutica para el tratamiento de un trastorno médico susceptible al tratamiento con un ligando del recepto de dopamina D3.
UY30284A 2006-04-14 2007-04-13 Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 UY30284A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06007923 2006-04-14
US79367106P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
UY30284A1 true UY30284A1 (es) 2007-11-30

Family

ID=38180343

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30284A UY30284A1 (es) 2006-04-14 2007-04-13 Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3

Country Status (8)

Country Link
US (1) US8383641B2 (es)
EP (1) EP2013179B1 (es)
JP (1) JP5232987B2 (es)
AR (1) AR060462A1 (es)
CA (1) CA2648543C (es)
MX (1) MX2008013114A (es)
UY (1) UY30284A1 (es)
WO (1) WO2007118859A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150355T1 (hr) 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
JPWO2010113834A1 (ja) 2009-03-30 2012-10-11 アステラス製薬株式会社 ピリミジン化合物
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
WO2013074965A1 (en) * 2011-11-16 2013-05-23 Microbiotix, Inc. Aminoalkyl phenol ether inhibitors of influenza a virus
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US11034700B2 (en) 2017-03-08 2021-06-15 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
HUE071890T2 (hu) 2019-01-31 2025-09-28 Takeda Pharmaceuticals Co Heterociklusos vegyületek és felhasználásuk

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW450954B (en) * 1998-05-14 2001-08-21 Pharmacia & Amp Upjohn Company Phenylsulfonamide-phenylethylamines useful as dopamine receptors
EP2371814A1 (en) 2004-10-14 2011-10-05 Abbott GmbH & Co. KG Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

Also Published As

Publication number Publication date
EP2013179A1 (en) 2009-01-14
AR060462A1 (es) 2008-06-18
MX2008013114A (es) 2008-10-21
CA2648543A1 (en) 2007-10-25
CA2648543C (en) 2015-06-02
US20090143383A1 (en) 2009-06-04
WO2007118859A1 (en) 2007-10-25
JP2009533397A (ja) 2009-09-17
EP2013179B1 (en) 2011-01-19
JP5232987B2 (ja) 2013-07-10
US8383641B2 (en) 2013-02-26

Similar Documents

Publication Publication Date Title
DOP2011000218A (es) Derivados de sulfonamida
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
CR20110016A (es) Compuestos quimicos 251
UY30284A1 (es) Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CR11119A (es) Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingozina 1-fosfato (sip)
UY31350A1 (es) (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos
DK2207770T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
BRPI0906444A8 (pt) compostos de 4-piridinona e seu uso para câncer
ECSP099518A (es) Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
PE20151607A1 (es) Formulaciones de compuestos organicos
BR112015004523A2 (pt) compostos de tetraciclina
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
CO6351744A2 (es) Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridini-3-il]-2-metil-4´-(trifluoro-metoxi)-[1,1´-bifenil]-3-carboxamida
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
ECSP055985A (es) Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis
CY1117483T1 (el) Συνθεσεις τροποποιημενης αποδεσμευσης επαλρεστατης ή ενος παραγωγου αυτης και μεθοδοι για χρηση των ιδιων
CR11665A (es) Farmacoforos duales-antagonistas muscarinicos de pde4
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170606